GE Aerospace Is Making a $12 Billion Acquisition. Here's What Investors Should Know.

GE Aerospace plans to acquire Consolidated Precision Products for $11.75 billion, funded with $7 billion of cash and the balance through new debt. CPP supplies about 25% of GE's aerospace-casting needs and is expected to generate roughly $2 billion of revenue in 2027, helping relieve a key production bottleneck against GE's approximately $210 billion backlog extending into the 2030s. The deal is expected to be accretive to adjusted EPS and free cash flow in year one, though antitrust review, increased leverage, and GE's near-40x P/E valuation are key risks.

Analysis

The strategic value is not CPP's standalone earnings but the option value of converting a constrained external input into controlled capacity. That can protect GE's engine-delivery cadence, aftermarket installed-base growth, and working-capital conversion; a single avoided production delay has outsized value where downstream service revenue carries materially higher lifetime margins than original equipment. The offset is that vertical integration reduces GE's flexibility if aerospace casting demand normalizes, while any requirement to maintain arm's-length supply to rival engine makers would preserve CPP's capacity burden without delivering the full scarcity advantage GE is underwriting.

The market should focus less on first-year accretion claims and more on purchase-price discipline, remedy terms, and incremental leverage. At a premium earnings multiple, even modest misses in synergy realization, deal-close timing, or free-cash-flow conversion can produce disproportionate multiple compression over the next 1-3 months. Over 6-18 months, successful integration would widen GE's delivery reliability versus RTX/Pratt & Whitney and Safran; conversely, a consent decree requiring nondiscriminatory supply, capacity carve-outs, or pricing controls materially weakens the strategic rationale.

Consensus likely treats regulatory review as a binary closing risk. The more relevant risk is a conditional approval that closes but limits preferential access, because GE would still absorb financing and integration costs while competitors retain access to a critical supplier. The recent share-price weakness is not automatically a buying opportunity: the key falsification points are management reducing free-cash-flow guidance, evidence of higher-than-expected debt-funded financing costs, or regulatory remedies that prevent GE from reserving incremental CPP capacity for its own programs.

Key Decisions for Investors

• Maintain GE as a watch-list long rather than chase before remedy details: initiate only if management reiterates post-close free-cash-flow targets and regulatory disclosures indicate no mandated capacity allocation or price restrictions for third parties. Target a 6-18 month holding period; exit on an FCF-guide reduction or material remedy disclosure.
• For existing GE exposure, buy 3-6 month downside protection around the regulatory decision window rather than add outright. The asymmetry is unfavorable if approval is conditional: plain approval is partly expected, while restrictive remedies can challenge both synergy assumptions and the premium valuation.
• Consider a small relative-value long GE / short RTX position only after confirmation that CPP capacity is being prioritized for GE programs. The trade isolates the potential delivery-reliability advantage versus Pratt & Whitney; close if RTX demonstrates comparable supply-chain normalization or GE agrees to broad third-party supply commitments.
• Monitor GE bond spreads and announced financing terms as the near-term signal. A sustained widening versus similarly rated industrial issuers, or debt pricing materially above management's implied acquisition return threshold, would indicate that equity estimates are underpricing balance-sheet drag.